retatrutide clinical trials safety retatrutide A new trial from Eli Lilly and Company suggests its experimental triple hormone drug, retatrutide, could become one of the next major medications in the rapidly growing weight loss and diabetes Retatrutide Long-Term Safety: What Happens

Neuro-humoral actions include modulation of hypothalamic appetite centers, leading to increased satiety and reduced caloric intake, as well as slowing of gastric emptying, which further contributes to appetite suppression and glycemic control [74]

Retatrutide is still being studied and is not fully approved yet, so long-term safety data are very limited

The glucagon component may also contribute to reduced hepatic lipid accumulation, which improves hepatic insulin sensitivity over time

Because both medications slow down your digestive system and signal fullness to the brain, they share the standard GLP-1 family side effects

Use our calculator for custom concentrations